Abstract Safety, tolerability and efficacy profiles of interferon beta (IFNβ) therapy in relapsing multiple sclerosis (MS) has been widely verified both in trial settings and in daily clinical practice. However, for a variable percentage of treated patients, it remains only partially effective. In this study, we reported the post-marketing experience of the efficacy of IFNβ therapy for a large cohort of MS patients regularly attending the MS Outpatient Clinic of "La Sapienza University" in Rome. In this cohort we also sought clinical and paraclinical variables responsible for the clinical course of MS during IFNβ therapy. Patients that received treatment with one of the IFNβ formulations for at least 1 year were included. Clinical outcomes (i.e., relapses and disability score) were monitored throughout the entire study period. Magnetic resonance imaging (MRI) scans were performed twice for each subject: at baseline and after 1 year of therapy. The occurrence of more than one relapse during the study period or a sustained disability progression in the Expanded Disability Status Scale (EDSS) score were considered as criteria for the definition of suboptimal clinical response to IFNβ therapy. During IFNβ therapy (number of patients 242, mean length of treatment 4.3±2.3 years) a reduction in the annualised relapse rate of 59% (p<0.001) was observed. Eighty-six patients (35%) fulfilled the criterion for defining "suboptimal responder" on the basis of relapses, and 69 (28.5%) did the same on the basis of EDSS sustained progression.
Introduction
Phase III trials [1] [2] [3] have demonstrated that interferon beta (IFNβ) reduces the frequency of multiple sclerosis (MS) attacks by approximately 30% and the number of new magnetic resonance imaging (MRI) lesions by 70% compared with placebo [4] [5] [6] , but a high degree of variability is present in terms of response among patients.
Demographic, clinical and biological parameters, such as age, disease duration, Expanded Disability Status Scale (EDSS) score, relapse rate before IFNβ therapy and the development of neutralising antibodies (NAbs) against IFNβ have been reported as potential predictive factors of therapeutic response in post-marketing studies [7] [8] [9] [10] [11] . Nevertheless, these studies reported conflicting results in relatively short-term follow-up (2-4 years). There are few long-term studies on MS patients treated with IFNβ investigating clinical and MRI features able to predict the longterm clinical outcome and providing clinicians with a model helpful in making decisions about preventive therapy over time. Recently, demographic, clinical and MRI variables as well as serum biological markers evaluated at baseline and after 12 months of treatment with IFNβ have been tested as predictors of long-term clinical outcome in RRMS patients [12] . Results from this study indicated that the presence of gadolinium enhancement, both at baseline and 1 year after IFNb commencement, was the unique variable associated with the number of relapses over the subsequent study period and T1 hypointense lesion load, i.e., "black holes", was the unique baseline factor associated with a higher risk of disability progression. Male gender and the presence of NAbs against IFNβ became significant predictors one year after the commencement of IFNβ therapy. It is worth noting, however, that results from that study were obtained in a small cohort of MS patients specifically selected to participate in a pilot phase II trial proving the efficacy of IFNβ in relapsing MS [13] . Because of the possible bias produced by the recruitment of a population with homogeneous demographic and clinical characteristics, results from that study need to be confirmed in a larger, non-selected cohort of MS patients. The purpose of the present study is in fact to investigate in a large sample of non-selected MS patients those individual or disease-related variables, if any, responsible for the clinical outcome of MS during a long-term treatment period with IFNβ. At the same time, this study enables us to confirm the efficacy of IFNβ therapy in relapsing MS, even in daily clinical practice.
Methods
Patients with clinically definite relapsing-remitting (RR) MS according the Poser Criteria [14] , receiving treatment for at least one year with one of the three IFNβ formulations approved as disease-modifying therapies for MS (Betaferon, Schering, 8 MIU s.c. every other day; Avonex, Biogen, 20 mcg i.m. once a week; Rebif, Serono, 22 or 44 mcg s.c., administered three times weekly) were considered in this retrospective study. The time window for a patient to be included in this survey was in fact 10 years (ranging from 1994 to 2004). We collected demographic data and clinical variables recorded during each visit: sex, age at IFNβ commencement, number of clinical exacerbations before and during IFNβ therapy, EDSS scores at the beginning of IFNβ (baseline) and every six months. Any other medical event occurring as a result of IFNβ treatment was collected as well. Also, we collected MRI data recorded at baseline and at one year of IFNβ treatment, focusing on measures of subclinical disease activity such as enhancing lesions in post-contrast T1-weighted scans and hyperintense lesions on proton density and T2-weighted scans.
Relapse rate as well as EDSS changes occurring during the treatment period were considered as a measure of treatment efficacy. Clinical response to IFNβ was defined on the basis of the number of relapses and disability progression during the treatment period. We considered as "sub-optimal responders" either those patients who developed more than one relapse during the treatment period or those with an increase in EDSS score of at least 1 point confirmed in two consecutive visits separated by a 6-month interval. The effect of treatment on MRI indices of disease activity was measured by analysing the number of enhancing lesions on post-contrast T1-weighted images as well as the new T2 hyperintense lesions. Gadolinium-enhanced MRI scans were considered "active" by the presence of at least one enhancing lesion.
All the data have been analysed using SPSS software. Mean annualised relapse rate before and during IFNβ therapy for the entire population has been obtained as a result of the average between all the mean annualised relapse rates of each subject. Statistical significance between proportions was calculated using Pearson's Chi-squared test. Statistical significance between two continuous variables was calculated using the Student's independent-samples t-test. All p-values less than 0.05 were considered significant.
Results
We analysed data of 242 patients (169 females, 73 males) with a mean (±SD) age of 38±9.4 years (range 17-64), mean (±SD) disease duration of 10.5±5.7 years (range 2-34), median EDSS score of 1.5 (range 0-5.5) and mean IFNβ treatment duration of 4.3±2.3 years (range 1-11). Of them, 54 (22.3%) were treated with Betaferon, 45 (18.6%) with Avonex, 68 (28.1%) with Rebif 22 and 75 (31%) with Rebif 44. Twenty-five patients (10.3%) interrupted the IFNβ therapy after a mean time of 3.6±2.1 years because of disease progression (22) or lack of compliance (3). Of these, 20 (8.2%) began immunosuppressive treatment with mitoxantrone. As this study was not interested in evaluating any dose effect on clinical/MRI measures and the distribution of the three IFNβ formulations was fairly balanced among subjects, we analysed patients' data as a whole regardless of their treatment group. IFNβ treatment was therefore considered as effective if it produced the expected change in the clinical/MRI variables as previously indicated [1] [2] [3] .
The mean annualised relapse rate prior to IFNβ treatment was 0.9±0.84, whereas during therapy it was 0.37±0.54, with a percentage change of -59% (p<0.001). One hundred and eight patients (44.6%) remained relapsefree during their treatment period. Sixty-nine patients showed an increase in the EDSS score of at least 1 point; 173 had a stable or improved EDSS score. Twenty-seven patients (11.1%) showed both an EDSS progression and two or more relapses.
On the basis of the relapse's occurrence, 86 (35.5%) patients were considered "sub-optimal responders" (i.e., ≥2 relapses throughout the study period). In Table 1 we report demographic and clinical characteristics of the patients considered as "sub-optimal responders" according to the occurrence of relapses. There were no significant differences between the group of patients with less than 1 relapse and that of patients with 2 or more relapses.
The group of "sub-optimal responders" on the basis of disability was older than the responder group and its disease duration was significantly longer (Table 2 ).
In our cohort of patients we did not find a "gender effect" either on the occurrence of relapses or on disability progression during the treatment period. Interestingly, the EDSS change between baseline and the most recent neurological examination was higher in men than in women (0.6±1 vs. 0.3±0.9, p<0.05). Similarly, men showed a higher EDSS change between the visit at 1 year of IFNb therapy and the last visit with respect to women (0.4±0.8 vs.
0.2±0.9, p<0.05).
MRI data at the beginning of therapy and after the first year of therapy were available for 101 (41.7%) patients.
Forty-four (43.5%) patients had an active MRI scan at baseline, while only 20 (19.8%) patients showed an active scan at 1 year. Seventeen (16.8%) patients showed an active scan both at baseline and at 1 year.
There was no significant difference in terms of annualised relapse rate during the IFNβ therapy in the patients with and without an active baseline MRI scan. On the contrary, the patients with an active 1-year MRI scan had an annualised relapse rate during the treatment period higher than those without gadolinium enhancement (0.7±0.9 vs. 0.2±0.3, p<0.001) (Fig. 1a) . Moreover, the mean annu- alised relapse rate value in those patients (n=32) with at least one new T2 hyperintense lesion at the 1-year MRI scan was higher than in patients (n=69) with unchanged MRI lesion burden (0.6±0.8 vs. 0.2±0.3, p<0.01) (Fig. 1b) . In particular, patients with an active 1-year MRI scan had a higher risk of developing ≥2 relapses during the treatment (OR 3.6, CI 95% 1.3-10.2). Similarly, patients with one or more new T2 hyperintense lesions at 1-year MRI scan had a higher risk of developing ≥2 relapses during the treatment (OR 2.8, CI 95% 1.1-7.3).
Discussion
Phase III clinical trials have convincingly demonstrated the beneficial effects of IFNβ in patients with RRMS, but there is a high degree of variability in the response from one patient to another [1] [2] [3] 15] . Post-marketing studies have confirmed that IFNβ reduces the frequency and severity of relapses, demonstrating a less consistent effect on the progression of disability [7] [8] [9] [10] [11] . Similarly, although IFNβ has been shown to be effective in reducing MRImeasured MS activity in phase III trials [4] [5] [6] , marked between-patient heterogeneity of treatment response in terms of enhancing lesion reduction during the treatment period has been demonstrated [16] [17] [18] .
In this study, when we adopted predefined criteria of clinical response on the basis of relapse occurrence and EDSS score, we found that the majority of the patients responded to IFNβ (64% according to relapse occurrence, 71.5% according to EDSS progression). MRI results confirmed the clinical efficacy, showing that 68% of patients did not develop new T2 lesions during the first year of treatment and 80.2% did not have an enhancing lesion at the 1-year scan. The sensitivity of these MRI measures to detect a treatment effect makes them a useful tool to identify patients at high risk of relapse [16] [17] [18] . Our study showed in fact that the development of at least one new T2 lesion as well as the presence of enhancing lesions at the one-year MRI scan were associated with the occurrence of relapses throughout the treatment period. These data are consistent with previous reports that used MRI disease activity measures during treatment with IFNβ-1a to identify the therapeutic response [12, 19] . A post hoc analysis from the original study on intramuscular IFNβ-1a for disease progression in relapsing MS indicated that patients with significant disease activity measured by new T2 lesions while taking IFNβ had outcomes very similar to placebo-treated patients [19] . It is still questionable, however, whether it could be desirable to use either enhancing lesions or new T2 lesions as the best measure to evaluate IFNβ anti-inflammatory activity. Detecting gadolinium-enhancing lesions on a single MRI scan has the advantage of being an easy procedure and does not require a baseline assessment; however, as demonstrated here, approximately 18% of patients who could be considered as responders on the basis of gadolinium activity suppression actually present new lesions on T2-weighted images, confirming that T2 lesions are more sensitive, although less specific than enhancing lesions, to detect inflammatory activity. The higher sensitivity of T2 compared to gadolinium-enhanced lesions is because new T2 lesions usually persist, whereas an area of enhancement lasts on average one month.
Clinical and demographic characteristics seem to be an additional factor in influencing the clinical outcome once IFNβ therapy is prescribed. As expected, a younger age and shorter disease duration were associated with a better clinical response to treatment. Moreover, our study showed that the degree of EDSS worsening is greater in men than in women, supporting the findings of a more favourable response to IFNβ therapy in women than men [20] .
In conclusion, the present study suggests that 60%-80% of patients on treatment with IFNβ show a satisfactory clinical or MRI response to therapy. Moreover, it supports the routine use of MRI to monitor disease activity during IFNβ treatment in order to facilitate early identification of those patients who could possibly benefit from a different therapeutic approach.
